Showing results (101-110 of 368) with videos related to

Sort By:
Pageof 37
European Heart Journal|September 11, 2019
Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trialDavid Fitchett, Silvio E Inzucchi, Christoph Wanner, et al.
The Lancet. Diabetes & Endocrinology|July 2, 2017
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trialDavid Z I Cherney, Bernard Zinman, Silvio E Inzucchi, et al.
Diabetes, Obesity & Metabolism|January 5, 2019
Composite cardiovascular risk factor target achievement and its predictors in US adults with diabetes: The Diabetes Collaborative RegistryWenjun Fan, Yang Song, Silvio E Inzucchi, et al.
JAMA|July 3, 2003
Metformin and thiazolidinedione use in Medicare patients with heart failureFrederick A Masoudi, Yongfei Wang, Silvio E Inzucchi, et al.
The Journal of Clinical Endocrinology and Metabolism|June 3, 2020
Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME TrialSilvio E Inzucchi, Kamlesh Khunti, David H Fitchett, et al.
AJP Reports|August 15, 2013
Clitoral epidermoid cyst presenting as pseudoclitoromegaly of pregnancyJing W Hughes, Marsha K Guess, Adam Hittelman, et al.
Diabetes, Obesity & Metabolism|October 21, 2020
Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetesSilvio E Inzucchi, Melanie J Davies, Kamlesh Khunti, et al.
Annals of Vascular Surgery|February 2, 2024
Insulin Requirement and Infrainguinal Bypass Outcomes in Patients with Peripheral Arterial DiseaseDana Alameddine, Keyuree Satam, Martin Slade, et al.
Circulation. Heart Failure|May 28, 2019
Understanding Contemporary Use of ThiazolidinedionesSuzanne V Arnold, Silvio E Inzucchi, Justin B Echouffo-Tcheugui, et al.
Cardiovascular Diabetology|July 11, 2024
Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trialDavid Fitchett, Bernard Zinman, Silvio E Inzucchi, et al.
Pageof 37